IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v471y2011i7339d10.1038_nature09870.html
   My bibliography  Save this article

FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Author

Listed:
  • Trever G. Bivona

    (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20)

  • Haley Hieronymus

    (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20)

  • Joel Parker

    (Expression Analysis, Inc.)

  • Kenneth Chang

    (Cold Spring Harbor Laboratory, One Bungtown Road)

  • Miquel Taron

    (Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
    Pangaea Biotech, USP Dexeus University Institute, Sabino Arana 5 - 19, 08028 Barcelona, Spain)

  • Rafael Rosell

    (Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
    Pangaea Biotech, USP Dexeus University Institute, Sabino Arana 5 - 19, 08028 Barcelona, Spain)

  • Philicia Moonsamy

    (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20)

  • Kimberly Dahlman

    (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20)

  • Vincent A. Miller

    (Thoracic Medical Oncology, Memorial Sloan-Kettering Cancer Center)

  • Carlota Costa

    (Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Carretera Del Canyet s/n
    Pangaea Biotech, USP Dexeus University Institute, Sabino Arana 5 - 19, 08028 Barcelona, Spain)

  • Gregory Hannon

    (Cold Spring Harbor Laboratory, One Bungtown Road
    Howard Hughes Medical Institute)

  • Charles L. Sawyers

    (Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 20
    Howard Hughes Medical Institute)

Abstract

Targeting EGFR in lung cancers A substantial proportion of lung cancers in non-smokers are associated with mutations in EGFR, the gene for the epidermal growth factor receptor. EGFR tyrosine kinase inhibitors such as erlotinib are used to treat such tumours, but not all patients respond and some even develop resistance. Now, an RNA interference screen for modifiers of the EGFR inhibitor response suggests a potential strategy for improving lung cancer therapy. The screen reveals that inhibition of CD95/Fas and NF- B signalling enhances the response to EGRF inhibitors in vitro and in vivo. In patients with lung cancer who are treated with EGFR inhibitors, expression of the NF-κB inhibitor IκB is associated with a better response and longer survival, suggesting that combining NF-κB pathway and EGFR inhibitors may prove clinically useful.

Suggested Citation

  • Trever G. Bivona & Haley Hieronymus & Joel Parker & Kenneth Chang & Miquel Taron & Rafael Rosell & Philicia Moonsamy & Kimberly Dahlman & Vincent A. Miller & Carlota Costa & Gregory Hannon & Charles L, 2011. "FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR," Nature, Nature, vol. 471(7339), pages 523-526, March.
    • Handle: RePEc:nat:nature:v:471:y:2011:i:7339:d:10.1038_nature09870
    DOI: 10.1038/nature09870
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/nature09870
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1038/nature09870?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:471:y:2011:i:7339:d:10.1038_nature09870. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.